CompletedNCT05479292

Allocating Resources for Cancer Care in Times of the Sars-CoV-2 Outbreak. Health Care Research

Studying Non-specific autoimmune cerebellar ataxia without characteristic antibodies

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Technische Universität Dresden
Principal Investigator: Jochen Schmitt, Dr. med.
Technische Universität Dresden
Intervention: Sars-CoV-2 outbreak(other)
Enrollment: 6500 target
Eligibility: 4 years · All sexes
Timeline: 2019 – 2020

Study locations (1)

ZEGV, Dresden, Saxony, Germany

Collaborators

German Federal Ministry of Education and Research · AOK PLUS · Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg · Ruhr University of Bochum

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05479292 on ClinicalTrials.gov

Other trials for Non-specific autoimmune cerebellar ataxia without characteristic antibodies

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT06606366
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
Centre Antoine Lacassagne

See all trials for Non-specific autoimmune cerebellar ataxia without characteristic antibodies →

← Back to all trials